These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cholinesterase inhibitors for Parkinson's disease dementia. Maidment I; Fox C; Boustani M Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494 [TBL] [Abstract][Full Text] [Related]
24. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420 [TBL] [Abstract][Full Text] [Related]
25. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Li Y; Hai S; Zhou Y; Dong BR Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590 [TBL] [Abstract][Full Text] [Related]
30. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079 [TBL] [Abstract][Full Text] [Related]
31. Folic acid with or without vitamin B12 for cognition and dementia. Malouf M; Grimley EJ; Areosa SA Cochrane Database Syst Rev; 2003; (4):CD004514. PubMed ID: 14584018 [TBL] [Abstract][Full Text] [Related]
37. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Fioravanti M; Flicker L Cochrane Database Syst Rev; 2001; 2001(4):CD003159. PubMed ID: 11687175 [TBL] [Abstract][Full Text] [Related]
39. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Forette F; Anand R; Gharabawi G Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894 [TBL] [Abstract][Full Text] [Related]